Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Oral Dose
  4.  » 
  5. Development & Bioavailability
  6.  » 
  7. Bioavailability Enhancement
  8.  » Catalent Spray Drying Technology

Catalent Spray Drying Technology


Poorly soluble compounds continue to make up a large share of the pharmaceutical development pipeline. Spray drying has been proven for particle size engineering and known to improve the bioavailability of poorly soluble compounds.

A spray dried dispersion (SDD) is an amorphous molecular dispersal of a drug in a polymer matrix, created by dissolving drug and polymer in a solvent and then spray-drying the solution.

Catalent offers spray drying solutions from early-phase development through to clinical supply, and scale-up to commercial volumes of finished dose forms. In 2019, Catalent expanded the capacity of its global spray drying operations through an agreement with EUROAPI, under which they provide Catalent with access to spray-drying manufacturing capabilities at their Haverhill, UK facility. With subsequent additional investment into the site to expand its SDD capabilities, and alongside Catalent’s global network of downstream dosage form manufacturing facilities, Catalent is well positioned to serve our global customers with end-to-end SDD solutions.


  • Buchi B-290
  • ProCepT 4M8-TriX
  • GEA Niro SD Micro
  • GEA Niro Mobile Minor (x2)
  • Buchi B-290
  • ProCepT 4M8-TriX
  • GEA Niro SD Micro
  • GEA Niro Mobile Minor (x2)
  • GEA Niro PSD2
  • GEA Niro PSD4

Back to top


A widely used processing technology, spray-drying offers numerous advantages, including:

  • Enhanced bioavailability of poorly soluble compounds
  • Consistent particle size distribution
  • Long-term stability
  • Robust, scalable process
  • Higher drug loading
  • Enables taste masking or controlled release dosage forms

Back to top


Expertise in formulation and process development is combined with proven capabilities in spray drying to overcome difficult product development challenges.

Catalent’s solutions include:

  • Full analytical and physical characterization
  • Pre-formulation testing, formulation, and process development
  • Organic and aqueous solvent processing of potent and non-potent molecules
  • R&D and cGMP manufacturing: From early development through to early clinical trial supply (Phase 1 and 2a)
  • The broadest selection of downstream processing technologies including granulation, roller compaction, tableting, and stick pack packaging.

Back to top


Catalent offers seamless transition and tech transfer from our early-development sites to strategically located commercial finished dose manufacturing at sites in Europe and the U.S.

Key scale-up and commercial capabilities include:

  • Formulation and process optimization
  • Organic and aqueous solvent processing of potent and non-potent molecules
  • Integrated teams and process alignment for seamless transfer and scale-up
  • cGMP manufacturing (Phase 2b to commercial scale)
  • Flexibility to scale solutions from orphan programs and pediatric variants to large-scale blockbuster products
  • Full range of granulators, blenders, tablet presses and encapsulators to support a diverse variety of finished dosage forms
  • Clinical to commercial primary and secondary packaging solutions including bottles, blisters and stick packs.

Back to top


  • Faster to Market – Move quickly and efficiently from early development through the final phases of process refinement to commercial-scale manufacturing
  • Deep Expertise – Highly skilled scientists and engineers with decades of solid dose and spray drying handling experience
  • Keep it Simple – Integrated teams to support tech transfers and scale-up to commercial volumes, with simplified project management protocols that reflect our experience across many molecules and dose forms

Back to top


The fastest and most effective way to unlock the potential of your molecule is to follow a rigorous, data-driven, parallel screening of appropriate available formulation technologies. We developed OptiForm® Solution Suite to do this quickly and efficiently for small molecules and OptiForm® Solution Suite Bio for your large molecules.

Other Bioavailability Enhancement Technologies:

Catalent can partner with you to accelerate and optimize your molecule through the clinic and all the way to market, ensuring robust and scalable formulations, and integrated clinical manufacturing to accelerate your program with full clinical packaging and distribution services as well as scale-up and commercial supply.